The nasal spray, used to vaccinate children and youths against flu, was the source of tensions between British-Swedish AstraZeneca and the Swiss Federal Office for Public Health (FOPH), it was reported earlier this week.
The Keystone-SDA news agency wrote on Sunday that the FOPH claimed AstraZeneca was asking for remuneration at more than twice the price of comparable products.
Following the pricing disagreements, the company thus decided to simply give up on efforts to put the vaccine on the market and to give the 10,000 doses away, rather than waiting until they expired. They are currently sitting in a warehouse owned by a third-party company in canton Bern.
Astrazeneca says that the vaccines can be ordered free of charge by doctors and medical personnel, on condition that they also pass it on free of charge to patients.
More
More
How vaccine technology, choice and supply work in Switzerland
This content was published on
The Swiss Covid-19 vaccination campaign is up and running. How do the vaccine technologies work and compare?
According to the latest estimates by the FOPH, the flu situation in Switzerland is not currently more acute than in previous years. There were fears that this autumn-winter could see a severe flu season after the past few years dominated by Covid-19.
In mid-October the FOPH nevertheless issued a flu vaccination recommendation to all people belonging to a risk category, as well as their family members.
Employees in Switzerland increasingly stressed at work
This content was published on
The proportion of people in Switzerland who are stressed at work has increased by 5% over ten years, according to the Federal Statistical Office.
This content was published on
F/A-18 fighter jets will practice take offs and landings on the A1 motorway between Payerne and Avenches in canton Vaud on June 5.
Swisscom finalises financing for Vodafone Italia takeover
This content was published on
Telecoms group Swisscom has taken the next step in its takeover of Vodafone Italia and secured financing for the deal, the company said on Thursday.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.